Biogena Group Invest AG (WBO:BIO) Other Stockholders Equity: €3.88 Mil (As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:BIO Biogena Group Invest AG WBO:BIO
61 GF Score
Price €5.25
GF Value €3.49
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biogena Group Invest AG Other Stockholders Equity?

Biogena Group Invest AG WBO:BIO +0.93% 61 Other Stockholders Equity is €3.88 Mil as of Jan. 2026. GuruFocus rates WBO:BIO with a GF Score™ of 61/100 and a GF Value™ of €3.49 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Biogena Group Invest AG's Other Stockholders Equity for the quarter that ended in Jan. 2026 was €3.88 Mil.

Biogena Group Invest AG's quarterly Other Stockholders Equity declined from Jan. 2024 (€3.89 Mil) to Jan. 2025 (€3.88 Mil) but then increased from Jan. 2025 (€3.88 Mil) to Jan. 2026 (€3.88 Mil).

Biogena Group Invest AG's annual Other Stockholders Equity declined from Jan. 2024 (€3.89 Mil) to Jan. 2025 (€3.88 Mil) but then increased from Jan. 2025 (€3.88 Mil) to Jan. 2026 (€3.88 Mil).

Biogena Group Invest AG Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Biogena Group Invest AG's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biogena Group Invest AG Other Stockholders Equity Chart

Biogena Group Invest AG Annual Data
Trend Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Other Stockholders Equity
Get a 7-Day Free Trial 3.89 3.89 3.89 3.88 3.88

Biogena Group Invest AG Semi-Annual Data
Jan20 Jan21 Jan22 Jan23 Jan24 Jan25 Jan26
Other Stockholders Equity Get a 7-Day Free Trial 3.89 3.89 3.89 3.88 3.88
WBO:BIO
61GF Score
Biogena Group Invest AG WBO:BIO
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biogena Group Invest AG Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €3.88 Mil mean?
Biogena Group Invest AG (WBO:BIO) has a Other Stockholders Equity of €3.88 Mil as of Jan. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Biogena Group Invest AG and its competitors.
Is Biogena Group Invest AG's Other Stockholders Equity too high?
Biogena Group Invest AG's current Other Stockholders Equity is €3.88 Mil. Overall, Biogena Group Invest AG has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biogena Group Invest AG's Other Stockholders Equity compare to KHC and GIS?
Biogena Group Invest AG's Other Stockholders Equity of €3.88 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Consumer Packaged Goods company?
A good Other Stockholders Equity depends on the Consumer Packaged Goods industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Biogena Group Invest AG and its competitors. Biogena Group Invest AG's current Other Stockholders Equity is €3.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogena Group Invest AG stock overvalued right now?
Based on GuruFocus' analysis, Biogena Group Invest AG (WBO:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is €3.49, compared to a current price of €5.25 — trading 50.4% above its estimated fair value. The current Other Stockholders Equity is €3.88 Mil. Biogena Group Invest AG's overall GF Score™ is 61/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Biogena Group Invest AG (WBO:BIO), the current Other Stockholders Equity is €3.88 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biogena Group Invest AG (WBO:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biogena Group Invest AG stock appears to be overvalued. The current stock price of €5.25 is trading 50.4% above its estimated GF Value™ of €3.49. GuruFocus considers Biogena Group Invest AG to be Significantly Overvalued.

Key valuation signals for WBO:BIO:

  • Other Stockholders Equity: €3.88 Mil
  • GF Value™: €3.49 vs. price of €5.25 (50.4% above fair value)
  • GF Score™: 61/100 with 7 warning signs

No single metric tells the full story. See the WBO:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biogena Group Invest AG Business Description

Address Strubergasse 24, Salzburg, AUT, 5020
Biogena Group Invest AG is a holding company. It is engaged in the development and distribution of products and services in the field of health and nutrition. In particular, the focus is on iron, mineral and osteoporosis product innovations and new integrated solutions in the area of workplace health promotion. Its products include vitamin, mineral, enzymes, medicinal mushrooms, among others.
61GF Score

Get the complete analysis for WBO:BIO

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.25
Price
€3.49
GF Value